Ropinirole
- Generic Name
- Ropinirole
- Brand Names
- Requip
- Drug Type
- Small Molecule
- Chemical Formula
- C16H24N2O
- CAS Number
- 91374-21-9
- Unique Ingredient Identifier
- 030PYR8953
- Background
Ropinirole, also known as ReQuip, is a non-ergoline dopamine agonist used in Parkinson's disease and restless legs syndrome , . It is manufactured by GlaxoSmithKline Pharmaceuticals. Ropinirole was initially approved in 1997 by the FDA for the management of Parkinson's disease. In 2005, it was the first drug approved in the US for the management of primary ...
- Indication
For the treatment of the signs and symptoms of Parkinson's disease and for the treatment of primary moderate-severe restless legs syndrome .
- Associated Conditions
- Idiopathic Parkinson's Disease, Moderate restless legs syndrome (RLS), Parkinson's Disease (PD), Severe restless legs syndrome (RLS)
- Associated Therapies
- -
A Clinical Research Study Evaluating Ropinirole Treatment For Restless Legs Syndrome (RLS)
- Conditions
- First Posted Date
- 2005-09-26
- Last Posted Date
- 2016-09-15
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 140
- Registration Number
- NCT00225862
- Locations
- 🇺🇸
GSK Investigational Site, Wenatchee, Washington, United States
Ophthalmologic Safety Study of Pramipexole Immediate Release (IR) Versus Ropinirole in Early Parkinson's Disease (PD) Patients
- First Posted Date
- 2005-09-05
- Last Posted Date
- 2014-03-14
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 246
- Registration Number
- NCT00144300
- Locations
- 🇺🇸
248.538.00010 Boehringer Ingelheim Investigational Site, New York, New York, United States
🇺🇸248.538.00013 Boehringer Ingelheim Investigational Site, Atlanta, Georgia, United States
🇺🇸248.538.00006 Boehringer Ingelheim Investigational Site, Philadelphia, Pennsylvania, United States
Study Evaluating Sumanirole for the Treatment of the Signs and Symptoms of Early Parkinson's Disease.
- Conditions
- First Posted Date
- 2002-05-09
- Last Posted Date
- 2006-06-07
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 600
- Registration Number
- NCT00036218
- Locations
- 🇵🇷
Pfizer Investigational Site, Carolina, Puerto Rico
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.